Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis*
References (14)
- et al.
Epidemiology and outcomes of osteoporotic fractures
Lancet
(2002) - et al.
Compliance with drug therapies for the treatment and prevention of osteoporosis
Maturitas
(2004) - et al.
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study
Clin Ther.
(2002) - et al.
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate
Maturitas
(2004) - et al.
Predictors of long-term persistence on statins in a subsidized clinical population
Value Health
(2000) - et al.
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, non-randomized, observational study
Clin Ther.
(2004) Osteoporosis prevention, diagnosis, and therapy
JAMA
(2001)
There are more references available in the full text version of this article.
Cited by (0)
- *
This work was presented in part at the international Society for Pharmacoeconomics and Outcomes Research 7th Annual European Congress, October 24–26, 2004, Hamburg, Germany, and Osteologie 2005, March 3–5, 2005, Basel, Switzerland.
Copyright © 2006 Published by Elsevier Inc.